Abhinav Sidana, MD, a urologic oncologist at the University of Chicago Medicine (UChicago Medicine), has performed the first ...

BioProtect’s lead product is a spacer system designed to protect healthy tissues during radiation therapies for prostate ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test at the end of this month. Prolaris will be the ...

Olympus Corporation (Olympus), a global MedTech company committed to advancing endoscopy-enabled care, announced today it has ...

TOKYO- Olympus is expanding its cancer care portfolio with the acquisition of a medtech company based in Israel. Olympus is ...

Although the use of tissue-based gene expression testing for prostate cancer was found to be “highly variable in the United States at the regional level,” distinct regional trajectories of commercial ...

Cleveland Clinic’s commercialization arm, Innovations, has spun off its fifth company this year in a joint project with an existing Cleveland startup. The new company is scooping up cancer diagnostic ...

Timing and uptake of germline testing in patients with somatic BRCA1/2 pathogenic or likely pathogenic variants in solid tumors: A real-world study from community oncology practices. Identifying ...

Total and anatomically contextualized quantitative 18F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression-free survival in patients with prostate cancer. This is an ...

A new podcast fronted by writer, comedian and broadcaster Jon Holmes is aiming to help men better understand their prostate cancer treatment options ...